MESA LABORATORIES INC /CO/ 10-Q

Item 5. Other Information   The following of our directors or officers entered into written plans for the purchase or sale of our securities intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5 - 1 (c) (each, a "trading arrangement") on the dates indicated:   Director John Schmieder entered into a trading arrangement on June 14, 2023 . The trading arrangement was effective through September 15, 2023 . The trading arrangement contemplated that Mr. Schmieder could sell up to 7,000 shares of Mesa Labs' common stock, subject to certain conditions.    Chief Financial Officer John Sakys entered into a trading arrangement on August 23, 2023 . The trading arrangement is effective through April 2, 2024. The trading arrangement contemplates that Mr. Sakys may exercise up to 2,500 non-qualified stock options and sell the resulting 2,500 shares of Mesa Labs' common stock, subject to certain conditions.   Senior Vice President of Continuous Improvement Brian Archbold entered into a trading arrangement on September 14, 2023 . The trading arrangement is effective through April 2, 2024 . The trading arrangement contemplates that Mr. Archbold may exercise 710 non-qualified stock options and sell the resulting 710 shares of Mesa Labs' common stock, subject to certain conditions. The trading arrangement further contemplates that Mr. Archbold may sell an additional 1,500 shares of Mesa Labs' common stock, subject to certain conditions.       Page 22 Table of Contents   Item 6. Exhibits   Exhibit No. Description of Exhibit 3.1 Amended and Restated Articles of Incorporation of Mesa Laboratories, Inc. (incorporated by reference from exhibit 3.1 to the Current Report on Form 8-K filed August 25, 2023 (Commission File Number: 000-11740)). 3.2 Amended and Restated Bylaws of Mesa Laboratories, Inc. (incorporated by reference from exhibit 3.1 to the Current Report on Form 8-K filed on May 10, 2019 (Commission File Number: 000-11740)). 10.1+ Amendment No. 2 to Credit Agreement dated as of October 5, 2023 among the Company, the lenders party thereto, and JPMorgan Chase Bank, NA., as administrative agent. 31.1+ Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2+ Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1* Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2* Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS+ XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH+ Inline XBRL Taxonomy Extension Schema Document. 101.CAL+ Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF+ Inline XBRL Taxonomy Extension Definitions Linkbase Document 101.LAB+ Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE+ Inline XBRL Taxonomy Extension Presentation Linkbase Document 104+ Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*).   + Filed herewith * Furnished herewith   Page 23 Table of Contents   Signatures   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.     MESA LABORATORIES, INC. (Registrant)     DATED: November 6, 2023 BY: /s/ Gary M. Owens . Gary M. Owens Chief Executive Officer             DATED: November 6, 2023 BY: /s/ John V. Sakys John V. Sakys Chief Financial Officer                         Page 24